Safety of concurrent T-DM1 and radiation therapy in HER2-positive breast cancer with residual disease after neoadjuvant chemotherapy.

Date publication

juin 2026

Journal

International journal of radiation biology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MERROUCHE Yacine , Dr JOUANNAUD Christelle , Dr HOTTON Judicaël

Tous les auteurs :
Beddok A, Girres L, Torielli P, Vigneau E, Ettalhaoui L, Hotton J, Jouannaud C, Mazza C, Lemoine A, Parent D, Roque A, Soibinet P, Vignot S, Merrouche Y, Guilbert P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42240561

Résumé

Trastuzumab emtansine (T-DM1) is the standard adjuvant treatment for HER2-positive breast cancer with residual disease after neoadjuvant chemotherapy. Its concurrent use with locoregional radiation therapy (RT) is increasingly common, yet data on pulmonary safety remain scarce.

Mots clés

Breast neoplasms, antibody-drug conjugates, radiation pneumonitis, receptor, ErbB-2, trastuzumab-emtansine

Référence

Int J Radiat Biol. 2026 06 4;:1-8